Zoetis Inc (NYSE:ZTS)

$ 190.71 0.72 (0.38%) Market Cap: 86.40 Bil Enterprise Value: 91.25 Bil PE Ratio: 37.18 PB Ratio: 17.36 GF Score: 97/100

Q1 2024 Zoetis Inc Earnings Call Transcript

May 02, 2024 / 12:30PM GMT

Release Date Price: $167.23 (+5.51%)

Transcript 10-Q8-K

Key Points

Positve

Zoetis Inc (ZTS) reported a strong first quarter with 12% operational revenue growth and a 15% increase in adjusted net income operationally.
The U.S. market led with a 16% growth, driven by the launch of the osteoarthritis pain franchise, showcasing strong domestic performance.
Zoetis Inc (ZTS)'s companion animal portfolio grew by 20% operationally, fueled by the human-animal bond and demand for new products like Librela and Solensia.
The company's strategic focus on innovation and science-driven products continues to pay off, with significant growth in new and existing markets.
Zoetis Inc (ZTS) has successfully expanded its market share in the parasiticides category, moving from #5 to #2, driven by products like Simparica and Simparica Trio.

Negative

Despite overall growth, the livestock segment of Zoetis Inc (ZTS) declined by 1% operationally, reflecting some challenges in this category.
Economic conditions in China and inventory destocking in the U.S. diagnostics sales model change presented headwinds, impacting growth.
The company faces ongoing competitive pressures, particularly in the dermatology and parasiticides categories, which could affect market share and pricing power.
Foreign exchange fluctuations continue to pose a risk, with a noted unfavorable impact on financial metrics such as adjusted gross margins.
Zoetis Inc (ZTS) is navigating a complex global market environment, with geopolitical tensions and economic uncertainty potentially affecting future performance.

Operator

Welcome to the First Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

The presentation materials and additional financial tables are currently posted on the Investor Relations section of zoetis.com. The presentation slides can be managed by you, the viewer, and will not be forwarded automatically.

In addition, a replay of this call will be available approximately 2 hours after the conclusion of the call via dial-in or on the Investor Relations section of zoetis.com.

(Operator Instructions) It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.

Steven Frank

Zoetis Inc. - VP of IR

Thank you, operator. Good morning, everyone, and welcome to the Zoetis First Quarter 2024 Earnings Call. I am joined today by Kristin Peck, our Chief Executive Officer; and Wetteny Joseph, our Chief Financial Officer.

Before we begin, I'll remind you that the slides presented on this call are available on the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.